NS Pharma

Executive Summary

NS Pharma, a subsidiary of Nippon Shinyaku, is a private biopharmaceutical company focused on developing innovative therapies for Duchenne muscular dystrophy (DMD) and other rare neuromuscular disorders. Founded in 2001 and headquartered in Paramus, New Jersey, the company specializes in small molecules and antisense oligonucleotides. Its lead product, viltolarsen (Viltepso), is an exon 53 skipping therapy approved in the US and Japan for DMD. NS Pharma continues to expand its pipeline with next-generation RNA-based treatments targeting additional exons and disease modifiers, leveraging its parent company's strong financial backing and manufacturing capabilities. Looking ahead, NS Pharma is poised to advance several key pipeline candidates. The company is working on label expansion efforts for viltolarsen globally, particularly in Europe, and is conducting clinical trials for a novel antisense oligonucleotide targeting exon 45 skipping. Additionally, NS Pharma is exploring combination therapies to enhance efficacy and durability. Despite competition from gene therapies and other exon-skippers, the company's proven regulatory pathway and deep expertise in DMD position it for steady growth. Near-term catalysts include regulatory decisions and clinical data readouts that could significantly impact valuation.

Upcoming Catalysts (preview)

• Q4 2026Viltolarsen EU approval decision40% success
• Q3 2026Phase 2 data for NS-035 (exon 45 skipping)50% success